Dexcom management check

DXCM · Health Care · Health Care Equipment · CEO Jacob Steven Leach

Filings as of

53
Management score, ranked 403rd of 487 · 49th of 60 in Health Care2 good · 4 to watch · 1 flaggedStrongest: pay for performance · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$72Peers$79

    What $100 became since fiscal 2021

    3943rd
    Detail

    $100 invested at the start of fiscal 2021 grew to $72, against $79 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8555th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.70 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.9% of net income

    $16.3m pay · $836.3m net income, FY2025

    0.1%1%3%10%
    2629th
    Detail

    $16.3m of reported pay in fiscal 2025, against $836.3m of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 2.0 years of pay

    417,457 shares ≈ $33.2m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $12.2m sold

    5056th
    Detail

    The CEO holds 417,457 shares, directly or through trusts (unvested awards not counted): about 2.0 years of pay. Light activity: no buys, $12.2m sold in six months. 25 of 25 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 429m2025 · 406m

    Diluted shares −2.4% a year; flagged above +2%

    0%10%20%

    Stock pay 3.4% of revenue

    8072nd
    Detail

    Diluted shares changed -2.4% a year over the last three fiscal years. Stock-based pay was 3.4% of revenue in the latest year.

  • Watch

    Is leadership stable?

    13 leadership filings in 3 years

    13 filings under 8-K 5.02 in 3 years

    0101420+
    6038th
    Detail

    13 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Flag

    Are the books clean?

    Red flags on file

    Since 2021

    • 0Restated
    • 1Auditor changes
    • 0Late filings
    • 010-K amended
    307th
    Detail

    1 auditor change (8-K 4.01) since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 15, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$8.7m$13.7m$36.1m$10020212022202320242025$72$79

Other key measures2025 Adjusted RevenueNon-GAAP Operating MarginRelative Total Shareholder Return

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025—$16.3m$13.0m$6.6m$72$79$836.3m
2024—$15.8m−$8.7m$5.6m$84$79$576.2m
2023—$15.7m$23.0m$5.0m$134$75$541.5m
2022—$15.4m$5.7m$4.4m$123$79$341.2m
2021—$12.0m$36.1m$5.0m$145$104$216.9m

Insiders and the CEO's stakeQuiet

President, CEO, and Director
Jacob Steven Leach
Shares held
417,457
At that filing's price
≈ $33.2m
Latest Form 4
Nov 8, 2026

Light activity: no buys, $12.2m sold in six months. 25 of 25 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldKevin R SayerExecutive Chair · 10b5-1 plan$8.3mAug 20, 2026
  • SoldMichael Jon BrownEVP Chief Legal Compliance Off · 10b5-1 plan$841kNov 16, 2026
  • SoldJon ColemanEVP, Chief Commercial Officer · 10b5-1 plan$723kJun 4, 2026
  • SoldNicholas AugustinosDirector · 10b5-1 plan$680kSep 15, 2026

Leadership and governance on file

20222023202420252026Leadership 18Red flags 1Votes 5
All 19 filings

Latest shareholder vote results: May 28, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $2.5bn returned to owners in buybacks and dividends, 99% of net income, and $720.7m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$418.1m$836.3m20212022202320242025Shares429m428m426m413m406m
Show the figures
Fiscal year20212022202320242025
Revenue$2.4bn$2.9bn$3.6bn$4.0bn$4.7bn
Net income$216.9m$341.2m$541.5m$576.2m$836.3m
Stock-based pay$113.4m$126.5m$150.8m$170.4m$159.6m
Buybacks$0$557.7m$688.7m$750.0m$500.0m
Dividends—————
Diluted shares429m428m426m413m406m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.